Protalix BioTherapeutics to Present at Three Upcoming Healthcare Conferences

Protalix BioTherapeutics to Present at Three Upcoming Healthcare Conferences

CARMIEL, Israel, June 1, 2009 (Business Wire) Protalix BioTherapeutics, Inc. (NYSE-AMEX: PLX),

today announced that Dr. David Aviezer, the Company s President and Chief Executive Officer, will

be presenting at 8th Annual Needham Life Sciences Conference in New York and the 8th

National Life Science and Technology Week ISLI-Biomed Israel 2009. Additionally, Dr. Einat Brill

Almon, the Company s Senior Vice President of Product Development, will be presenting at the 3rd

International Conference on Plant-Based Vaccines Antibodies in Italy.

The conference schedule is as follows:

8th Annual Needham Life Sciences Conference: Healthcare Today Tomorrow

Corporate Presentation, June 10 at 2:30 PM ET

New York Palace Hotel, New York, NY

A webcast of this presentation will be available at

3rd International Conference on Plant-Based Vaccines Antibodies

Presentation entitled, Novel enzyme replacement therapy for Gaucher disease: Ongoing

III trials with recombinant human glucocerebrosidase expressed in plant cells,

University of Verona, Verona, Italy

8th National Life Science and Technology Week ISLI-Biomed Israel 2009

Corporate Presentation, June 16 at the BioPharma Session, 4:20-6:20 PM IDT

David Intercontinental Hotel, Tel-Aviv, Israel

About Protalix BioTherapeutics

Protalix is a biopharmaceutical company. Its goal is to become a fully integrated

biopharmaceutical company focused on the development and commercialization of proprietary

recombinant therapeutic proteins to be expressed through its proprietary plant cell based

expression system. Protalix s ProCellEx(TM) presents a proprietary method for the expression of

recombinant proteins that Protalix believes will allow for the cost-effective, industrial-scale

production of recombinant therapeutic proteins. Protalix is conducting a phase III pivotal study

for its lead product candidate, prGCD, to be used in enzyme replacement therapy for Gaucher

disease, a lysosomal storage disorder in humans. Protalix has reached an agreement with the United

States Food and Drug Administration on the final design of the pivotal phase III clinical trial

through the FDA s Special Protocol Assessment (SPA) process. Protalix has completed enrollment for

this study and is treating patients in its pivotal phase III clinical trial in North America, South

America, Israel, Europe and South Africa. The study is monitored by an independent Data Monitoring

Committee including experts in the field, who monitor the on going safety data, which has recently

held their last scheduled meeting before the end of the trial. No serious adverse events have been

reported in the study. Protalix is also advancing additional recombinant biopharmaceutical drug

development programs.

The Trout Group, LLC

Telephone: 646-378-2927

Email: mnanus@troutgroup.com